Market Pulse Archives

April 21, 2021, 8:00 a.m. EDT

Vertex to study experimental gene-editing therapy as treatment for sickle cell, beta-thalassemia

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Vertex Pharmaceuticals Inc. (VRTX)
  • X
    CRISPR Therapeutics AG (CRSP)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Vertex Pharmaceuticals Inc. /zigman2/quotes/202259802/composite VRTX -1.67% said Tuesday it plans to pay $1.1 billion to Crispr Therapeutics AG /zigman2/quotes/201181046/composite CRSP +2.46% as part of a deal to test an experimental gene-editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia. The companies previously set up a development deal in 2015; as part of the amended one, which was announced Tuesday, Vertex will pay the Swiss genome-editing company a new $900 million upfront payment, with an additional $200 million available for meeting regulatory milestones, to test the investigational therapy for the blood disorders. In exchange, Vertex will provide 60% of costs and get 60% of profits from future sales if the therapy is approved and commercialized. Since the start of the year, Vertex's stock is down 6.8%, shares of Crispr Therapeutics have dropped 20.5%, and the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.90% is up 10.1%.

/zigman2/quotes/202259802/composite
US : U.S.: Nasdaq
$ 186.94
-3.17 -1.67%
Volume: 3.63M
Nov. 30, 2021 4:00p
P/E Ratio
22.45
Dividend Yield
N/A
Market Cap
$48.34 billion
Rev. per Employee
$1.83M
loading...
/zigman2/quotes/201181046/composite
US : U.S.: Nasdaq
$ 79.90
+1.92 +2.46%
Volume: 1.45M
Nov. 30, 2021 4:00p
P/E Ratio
16.79
Dividend Yield
N/A
Market Cap
$5.97 billion
Rev. per Employee
$1,754
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,567.00
-88.27 -1.90%
Volume: 3.94B
Nov. 30, 2021 4:15p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.